Small-cap Pharma Stock Surges 4% Amid Dalal Street Rally

Sudarshan Pharma Industries Sees Robust Growth in Q4 Earnings

Small-cap pharma stock Sudarshan Pharma Industries witnessed a 4% jump in its share price on Monday, 4 May, following the release of its Q4 results. The company's profit and revenue showed significant growth, indicating a strong operational momentum.

According to the results, the net profit for the March 2026 quarter rose 44.8% to ₹10.73 crore, compared to ₹7.41 crore in the same period last year. Revenue for the quarter increased 36.72% to ₹220.92 crore, up from ₹161.59 crore year-on-year. These numbers demonstrate the company's ability to consistently deliver robust growth across both quarterly and annual performance metrics.

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

For the full financial year, Sudarshan Pharma's net profit surged 55.64% to ₹23.30 crore from ₹14.97 crore in the previous year. Annual sales climbed 39.21% to ₹703.06 crore, compared with ₹505.04 crore in the preceding fiscal.

The company recently announced that Sachin Mehta will resign from his position as Chief Financial Officer (CFO), effective 1 May 2026. He will maintain his role as Joint Managing Director (JMD), ensuring a seamless leadership transition for the company. Mehta is related to the Chairman & Managing Director, Hemal Mehta.

Sudarshan Pharma is now searching for a successor to the CFO role, which Mehta will vacate on 1 May 2026. His continued role as JMD ensures that core strategic oversight remains with a seasoned promoter throughout this transition.

The company has faced operational difficulties in the past, including a cancelled plant project at Mahad that resulted in considerable expenses. However, its recent performance demonstrates impressive growth across multiple timeframes, showcasing ongoing investor enthusiasm and steady growth.

Read also: US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline

The stock has increased by 2.48% over the last week and 3.33% over the past two weeks, with a one-month return of 16.94%. Over the last three months, it has skyrocketed by 47.62%, reflecting strong recent trends. Year-to-date, the stock is up 14.69%, with a six-month return of 8.20%. Over the course of a year, it has appreciated by 16.28%. The longer-term results are especially remarkable, with the stock yielding a multi-bagger return of 310.05% over the last two years and 345.40% over three years, underscoring robust long-term wealth generation for investors.